Visual ERSP EEG System for Non-Invasive Amyloid Detection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for detecting amyloid deposition, particularly in Alzheimer's disease, schizophrenia, and autism spectrum disorder, are invasive, cumbersome, and lack non-invasive biomarkers for early detection and prediction of mental disorders.

Innovation Solution

A system and method utilizing visual event-related spectral perturbation (ERSP) measures, including stimulus-onset, motion-onset, and steady-state evoked potential (ssVEP) procedures, to generate diagnostic data from EEG information, segregating responses from subcortical magnocellular and parvocellular visual pathways using low and high spatial frequency stimuli.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If invasive methods such as CSF Aβ amyloid determination or PET imaging are used for amyloid detection, then measurement precision is improved, but ease of operation deteriorates and device complexity increases

Engineering Contradiction:

Improveamyloid detection accuracyVSAvoidscreening convenience

Core Design Contradiction:

Measurement precisionVSEase of operation

Solution Approach 1:

The patent replaces invasive mechanical/biological procedures (CSF sampling, PET imaging) with non-invasive optical/electrical measurement systems. Specifically, it uses near-infrared light absorption measurements and EEG-based visual evoked potential assessments to detect amyloid burden, substituting complex medical procedures with simpler optical and electrical measurement systems that can be performed in clinical settings without invasive interventions.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces intermediary biomarkers (blood-based amyloid markers, visual processing responses) that mediate between the target condition (amyloid deposition) and the measurement system. These intermediaries allow indirect detection of amyloid burden through blood samples or visual response measurements, avoiding the need for direct brain imaging or CSF analysis while maintaining diagnostic accuracy.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Measurement precision

If invasive methods such as CSF Aβ amyloid determination or PET imaging are used for amyloid detection, then measurement precision is improved, but device complexity increases

Engineering Contradiction:

Improveamyloid detection accuracyVSAvoiddetection system complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent replaces complex medical imaging devices (PET scanners) and laboratory-based CSF analysis systems with simpler optical measurement devices and EEG systems. The use of near-infrared spectroscopy and visual evoked potential recording employs standard clinical equipment rather than specialized research-grade imaging systems, thereby reducing device complexity while maintaining measurement precision for amyloid detection.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Reliability

If current amyloid detection methods are used, then reliability is improved, but loss of time increases due to cumbersome procedures

Engineering Contradiction:

Improvediagnostic reliabilityVSAvoidscreening time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent employs partial action by using simplified measurement protocols that capture essential diagnostic information without requiring complete comprehensive assessments. For example, it uses specific visual stimulus presentations and targeted EEG recordings rather than exhaustive neuropsychological testing, and uses blood-based amyloid markers rather than full PET imaging protocols, thereby reducing time investment while maintaining sufficient diagnostic reliability for screening purposes.

Inventive Principle:

Principle #16Partial or excessive action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach provides reliable discrimination between amyloid-negative and amyloid-positive individuals, serving as surrogate biomarkers for amyloid deposition, and correlates with regional amyloid distribution, even in healthy elders without cognitive symptoms, offering a non-invasive means for early detection and prediction of mental disorders.

Implementation Method 1

receiving electroencephalogram ('EEG') information from the patient(s) that can be based on the visual pattern(s)

Methodology Applied

Scientific EffectElectroencephalogram (EEG):

Implementation Method 2

a stimulus-onset event-related spectral perturbation (ESRP) procedure, (ii) a motion-onset ESRP procedure, or (iii) a steady-state evoked potential (ssVEP) procedure

Methodology Applied

Scientific EffectEvoked potential:

Data Source

PatentUS20250009280A1System, method, and computer-accessible medium for determining possibility/likelihood of mental disorder

Publication Date: 2025.01.09 RESEARCH FOUNDATION FOR MENTAL HYGIENE INC

AI summary

An exemplary system, method, and computer-accessible medium for generating diagnostic data associated with a likelihood a patient(s) developing a mental disease(s) can be provided, which can include, for example, providing a visual patterns to the patient(s), receiving electroencephalogram (EEG) information from the patient(s) that can be based on the visual pattern(s); and generating the diagnostic data based on the EEG information.